Free Trial

Merck KGaA (OTCMKTS:MKGAF) Sees Strong Trading Volume - Time to Buy?

Merck KGaA logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Trading volume jumped 46% to 848 shares on Monday, with the stock last trading at $128.27 versus a prior close of $136.37.
  • The company has a market cap of $17.59 billion, a P/E of 20.77, 50‑ and 200‑day simple moving averages near $138.20 and $139.61, and modest leverage (debt/equity 0.27) with a current ratio of 1.31.
  • Merck KGaA is a centuries‑old (founded 1668) Darmstadt‑based chemical and pharmaceutical group, privately controlled by the Merck family and organized into three main business units serving global markets.
  • Interested in Merck KGaA? Here are five stocks we like better.

Merck KGaA (OTCMKTS:MKGAF - Get Free Report) saw an uptick in trading volume on Monday . 848 shares were traded during trading, an increase of 46% from the previous session's volume of 581 shares.The stock last traded at $128.2740 and had previously closed at $136.37.

Merck KGaA Stock Down 0.1%

The firm has a market cap of $17.59 billion, a PE ratio of 20.77 and a beta of 0.96. The stock has a 50-day simple moving average of $138.20 and a two-hundred day simple moving average of $139.61. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27.

About Merck KGaA

(Get Free Report)

Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.

The company's operations are organized mainly into three businesses.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Merck KGaA Right Now?

Before you consider Merck KGaA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.

While Merck KGaA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines